CD8A and neoplasm: This includes increased expression of CD80, CD86, MHC I, and MHC II on dendritic cells, elevated levels of CD107 and IFN-γ in CD8+ T cells and NK cells, as well as inhibited expression of molecules related to metastasis and angiogenesis, ultimately inhibiting tumor progression and prolonging survival time (Huang et al., 2021).